STOPIMMO 250mg price in UAE

Overview

Welcome to Dwaey, specifically on STOPIMMO 250mg Capsules (Hard Gelatin) page.
This medicine contains an important and useful components, as it consists of Mycophenolate mofetil.
STOPIMMO 250mg is available in the market in concentration 250mg/Capsule and in the form of Capsules (Hard Gelatin).

TAHA PHARMA is the producer of STOPIMMO 250mg and it is imported from TUNISIA, The most popular alternatives of STOPIMMO 250mg are listed downward .

Mode Of Action

Mycophenolic acid acts by blocking purine synthesis of human lymphocytes through reversible inhibition of inosine monophosphate dehydrogenase. It also inhibits proliferation of both T- and B- lymphocytes.

Indication

Prophylaxis of acute renal graft rejection
Prophylaxis of cardiac graft rejection
Liver Transplant

Precaution

Teratogenic in animals; avoid inhalation or direct skin contact. Monitor patients for lymphoproliferative disorders; advise patient to limit exposure to sunlight/UV light. Active peptic ulcer disease. Severe renal impairment. Mycophenolate mofetil and mycophenolate sodium are not interchangeable. Perform CBCs; monitor for neutropenia. Lactation: Unknown whether drug is excreted in breast milk; avoid using, or do not nurse

Side Effects

>10% Hyperglycemia (44%)
Hypercholesterolemia (41%)
Hypomagnesemia (39%)
Dyspnea (37%)
Back pain (35%)
Increased blood urea nitrogen (BUN) (35%)
Leukopenia (34%)
Pleural effusion (34%)
Urinary tract infection (34%)
Increasing frequency of cough (31%)
Hypocalcemia (30%)
Hypertension (28%)
Abdominal pain (27%)
Peripheral edema (27%)
Anemia (26%)
Fever (23%)
Nausea (23%)
Hyperkalemia (22%)
Diarrhea (21%)
Infection (21%)
Headache (16%) 1-10% Melanoma (1.6-4.2%)
Other malignancies (0.7-2.1%)
Lymphoma (0.4-1%)
Opportunistic infection (including herpes)
Neutropenia
GI bleeding
Pulmonary fibrosis
Progressive multifocal leukoencephalopathy Potentially Fatal: Angioedema
anaphylaxis
fatal pulmonary fibrosis.

Contra indication

Pregnancy, lactation. Rare hereditary deficiency of hypoxanthine-guanine phosphoribosyltransferase (HGPRT), including Kelley-Seegmiller or Lesch-Nyhan syndrome.

Pregnancy and lactation

Pregnancy category: D

There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Interaction

Increased plasma levels of both drugs when combined with aciclovir, valaciclovir, ganciclovir and valganciclovir. Reduced absorption with colestyramine, magnesium- and aluminium hydroxide-containing products, sevelamer and other calcium-free phosphate binders. Reduced plasma levels with ciclosporin, metronidazole, quinolones, rifamycins. May reduce plasma levels of progestins; may reduce efficacy of oral contraceptives. Increased plasma levels with probenecid. May reduce efficacy of live vaccines.